Ani Pharmaceuticals (ANIP) Total Liabilities (2010 - 2026)

Ani Pharmaceuticals has disclosed Total Liabilities across 17 years of filings, most recently posting $859.7 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $859.7 million, up 1.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $859.7 million (up 1.26% YoY), and the FY2025 annual result was $899.7 million, up 5.11% from the prior year.
• Total Liabilities came in at $859.7 million for Q1 2026 at Ani Pharmaceuticals, down from $899.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $902.3 million in Q3 2025 to a low of $398.8 million in Q1 2022.
• The 5-year median for Total Liabilities is $440.1 million (2024), against an average of $608.9 million.
• Across the five-year window, Total Liabilities surged 100.25% in 2025 and increased 1.26% in 2026, its largest moves.
• Ani Pharmaceuticals' Total Liabilities stood at $421.5 million in 2022, then increased by 6.0% to $446.8 million in 2023, then surged by 91.56% to $855.9 million in 2024, then rose by 5.11% to $899.7 million in 2025, then declined by 4.44% to $859.7 million in 2026.
• The last three Total Liabilities figures came in at $859.7 million (Q1 2026), $899.7 million (Q4 2025), and $902.3 million (Q3 2025), per Business Quant data.